Selling a Dialysis Business in 2026: Multiples, Named Buyers, and the Operator Playbook
Quick Answer
A US dialysis center business in 2026 typically sells for roughly 5x to 11x EBITDA. The US dialysis market is extremely consolidated — DaVita Inc. (NYSE: DVA, ~3,000 centers) and Fresenius Medical Care (NYSE: FMS, ~2,600 US centers) together own approximately 80% of US dialysis centers. The buyer pool for independent dialysis centers is narrow but real, with the two giants plus US Renal Care (Bain Capital + Goldman Sachs + Leonard Green Partners), Innovative Renal Care (Nautic Partners), and Satellite Healthcare (non-profit) as the named acquirers. By profile: a single dialysis center with low census (60-100 patients) goes 5x-7x EBITDA; a multi-center independent group (2-5 centers, $1.5-4M EBITDA) goes 6x-8x; a regional independent platform (5-15 centers, $4-12M EBITDA) goes 7x-9x; a premium scale platform ($12M+ EBITDA, multi-state, integrated home dialysis, value-based kidney care positioning) reaches 8x-11x+ EBITDA. Active buyers include DaVita Inc. (NYSE: DVA, ~$12B+ revenue, the largest US dialysis provider), Fresenius Medical Care (NYSE: FMS, ~$20B+ global revenue), US Renal Care (PE-backed by Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners, the third-largest US dialysis provider), Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit, the largest US non-profit dialysis provider), Strive Health (value-based kidney care, Town Hall Ventures + CapitalG/Google), Dialyze Direct (PE-backed, home dialysis focus), American Renal Associates (DaVita subsidiary post 2021 acquisition), Centers for Dialysis Care (PE-backed regional). The biggest multiple drivers are patient census per center (60-100+ census per center is operating-benchmark), modality mix (home dialysis – HHD/PD – is the growth premium driven by CMS), value-based kidney care positioning (KCC, KCF, ETC models), water-treatment compliance, CMS Star ratings, and Medicare ESRD population served. Buyer-paid M&A advisory (CT Strategic Partners) costs the seller nothing.
If you own a dialysis center or independent dialysis group in 2026, the M&A market is concentrated. DaVita Inc. (NYSE: DVA) and Fresenius Medical Care (NYSE: FMS) together own approximately 80% of US dialysis centers, making this one of the most consolidated healthcare verticals. US Renal Care (Bain Capital + Goldman Sachs + Leonard Green Partners) is the third-largest with several hundred centers. Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit), and Strive Health (value-based kidney care) are other named participants. The market dynamics are shifting toward home dialysis (HHD + PD) and value-based kidney care models, which is creating new acquirer interest.
What the asset is worth depends on three things: (1) patient census per center (60-100+ is the operating-benchmark), (2) modality mix (home dialysis premium driven by CMS ETC and KCC value-based models), and (3) regulatory and compliance posture (water-treatment, CMS Star ratings, ESRD QIP performance). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.
What this guide covers
- Dialysis multiples 2026: 5x-7x for single-center low-census, 6x-8x for multi-center independent, 7x-9x for regional platforms, 8x-11x+ for premium scale with home dialysis + value-based kidney care positioning.
- Active buyers (narrow but real): DaVita Inc. (NYSE: DVA, ~3,000 centers, ~$12B+ revenue), Fresenius Medical Care (NYSE: FMS, ~2,600 US centers, ~$20B+ global revenue), US Renal Care (Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners), Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit), Strive Health (Town Hall Ventures + CapitalG/Google), Dialyze Direct.
- Market structure: DaVita + Fresenius own ~80% of US dialysis centers. Independent and PE-backed platforms compete for the remaining ~20%.
- PE sponsor activity: Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners (US Renal Care), Nautic Partners (Innovative Renal Care), Town Hall Ventures + CapitalG (Strive Health), plus multiple healthcare-services PE funds.
- Multiple drivers: patient census per center, modality mix (home dialysis HHD/PD growth premium driven by CMS ETC/KCC value-based models), value-based kidney care positioning, water-treatment compliance, CMS Star ratings, ESRD QIP performance, Medicare ESRD population.
- Things that compress the multiple: low census per center, hemodialysis-only without home modalities, weak CMS Star ratings, water-treatment compliance issues, no value-based kidney care positioning, single-payer concentration, single-state without expansion path.
- Sellers pay nothing on CT Strategic Partners’ buyer-paid advisory.
Named dialysis M&A transactions (2021-2025)
| Target | Buyer | Year | What it tells us |
|---|---|---|---|
| American Renal Associates | DaVita Inc. (NYSE: DVA) | 2021 | Major US dialysis consolidation; DaVita acquired the third-largest US dialysis provider. |
| Strive Health funding rounds | Town Hall Ventures + CapitalG (Google) + others | 2022-2024 | Value-based kidney care platform raised substantial venture funding; new subsegment validation. |
| US Renal Care continued growth | Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners | 2022-2025 | PE-backed third-largest US dialysis provider continues regional rollups. |
| Innovative Renal Care expansion | Nautic Partners | 2022-2025 | PE-backed dialysis platform continues regional rollups. |
| CMS ETC and KCC model rollouts | CMS (regulatory) | 2022-2025 | End-Stage Renal Disease Treatment Choices (ETC) + Kidney Care Choices (KCC) value-based models reshape industry economics. |
| Multiple regional center tuck-ins | DaVita + Fresenius + US Renal Care | 2022-2025 | The three largest dialysis providers continue regional center acquisitions where local market allows. |
The named buyer landscape
The Big Two (own ~80% of US dialysis centers)
- DaVita Inc. (NYSE: DVA, ~$12B+ revenue) — ~3,000 US centers, the largest US dialysis provider. Acquired American Renal Associates in 2021.
- Fresenius Medical Care (NYSE: FMS, ~$20B+ global revenue, ~$14B+ US) — ~2,600 US centers, second-largest. German parent company.
Third-tier PE-backed and large independent
- US Renal Care (Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners) — ~$2B+ revenue, third-largest US dialysis provider.
- Innovative Renal Care (Nautic Partners) — PE-backed regional platform.
- Satellite Healthcare (non-profit) — the largest US non-profit dialysis provider.
Value-based kidney care and home-dialysis platforms
- Strive Health (Town Hall Ventures + CapitalG / Google) — value-based kidney care platform.
- Dialyze Direct (PE-backed) — home dialysis focus.
- Centers for Dialysis Care (PE-backed) — regional.
PE sponsors active in this space
- Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners (US Renal Care), Nautic Partners (Innovative Renal Care), Town Hall Ventures + CapitalG / Google (Strive Health), plus multiple healthcare-services PE funds.
What each buyer will pay for vs. what they reject
- Will pay premium for: patient census per center (60-100+ census), modality mix with home dialysis (HHD home hemodialysis + PD peritoneal dialysis) capability, value-based kidney care model participation (CMS ETC End-Stage Renal Disease Treatment Choices, KCC Kidney Care Choices, KCF Kidney Care First), water-treatment compliance with state and CMS standards, CMS Star ratings (4+ stars is premium), ESRD QIP (Quality Incentive Program) high performance, named commercial in-network contracts, modern operating system.
- Will compress or reject: low census per center, hemodialysis-only without home modalities, weak CMS Star ratings (1-2 stars), water-treatment compliance issues, no value-based kidney care positioning, single-payer concentration, single-state without expansion path, open CMS or state-health-department survey findings.
The operator-level KPI playbook buyers will diligence
Census and modality
- Patient census per center: 60-100+ census is the operating benchmark.
- Modality mix: In-center hemodialysis (ICHD) %, home hemodialysis (HHD) %, peritoneal dialysis (PD) %.
- Home dialysis percentage: CMS targets 80% home dialysis or transplant; premium platforms are growing home modalities.
- Treatment volume per chair per day.
- Census growth rate.
Payer mix
- Medicare percentage: ESRD population is heavily Medicare (~85-90% typical).
- Commercial percentage: Pre-ESRD commercial coverage and Medicare-Advantage ESRD growth.
- Medicaid percentage.
- Workers’-comp / auto / other commercial.
- 21st Century Cures Act MA enrollment dynamics.
Value-based kidney care
- CMS ETC (End-Stage Renal Disease Treatment Choices) participation: Mandatory model in some HRRs; document.
- CMS KCC (Kidney Care Choices) participation: Voluntary value-based models.
- CKCC entity affiliations: Comprehensive Kidney Care Contracting entities.
- Performance metrics: Reduced hospitalizations, increased home modality, increased transplant.
Regulatory and quality
- CMS Five-Star ratings: 1-5 stars on the CMS Care Compare site.
- ESRD QIP (Quality Incentive Program) score: Annual score affects reimbursement; track historical.
- State health department survey history.
- Water-treatment compliance: AAMI standards, documented water-quality monitoring.
- Vascular access management: AVF vs. AVG vs. catheter percentage; AVF is the quality benchmark.
- Infection control (HAIs): Bloodstream infection rates.
Operating system and technology
- Dialysis-specific EMR: Acumen Nephrology, BluePrint by Fresenius, Inscope, Crown Web (CMS reporting).
- Patient registry and care coordination.
- Treatment data integration with dialysis machines.
Workforce
- Medical director and nephrologist coverage.
- Dialysis nurse and technician headcount.
- Social worker and dietitian on staff.
- Staff turnover.
Dangers and traps in dialysis M&A
1. Market concentration limits buyer pool
DaVita + Fresenius own ~80% of US dialysis centers. The buyer pool for independents is narrow: the two giants, US Renal Care, Innovative Renal Care, Satellite Healthcare, and a handful of value-based platforms.
2. Low census per center
Below 60 patient census per center compresses the multiple materially. Premium platforms operate 80-120+ census per center.
3. Hemodialysis-only without home modalities
CMS is pushing home dialysis (HHD + PD) via ETC and KCC value-based models. Hemodialysis-only operations face structural reimbursement pressure.
4. Weak CMS Star ratings or ESRD QIP performance
1-2 star ratings or low QIP scores signal quality issues and trigger reimbursement reductions.
5. Water-treatment compliance
Water-treatment failures (AAMI standards, microbial contamination) are deal-killers and create patient-safety liability.
6. Vascular access management
High catheter rate (vs. AVF/AVG) signals access management problems. CMS pushes AVF as the quality benchmark.
7. Single-payer or Medicare-Advantage exposure
21st Century Cures Act enabled MA enrollment for ESRD beneficiaries; track MA penetration carefully.
8. Open survey findings
State health department or CMS survey deficiencies must be resolved.
Our POV on dialysis M&A in 2026
Dialysis is the most consolidated healthcare-services vertical: DaVita + Fresenius own ~80% of US dialysis centers. Buyer pool for independents is narrow but real, dominated by the Big Two plus US Renal Care (Bain Capital + Goldman Sachs + Leonard Green), Innovative Renal Care (Nautic Partners), and value-based kidney care platforms (Strive Health). Multiples are mid-to-high single digits for the right asset, with premium for home dialysis modalities and value-based kidney care positioning.
Preparing your dialysis business for sale: 12-18 months out
- Get multi-year audited financials. Document census growth, modality mix, payer mix.
- Build home dialysis capability. HHD and PD modalities; document growth trajectory.
- Document CMS ETC + KCC value-based participation.
- Improve CMS Star ratings and ESRD QIP performance.
- Confirm water-treatment compliance. AAMI standards, microbial monitoring.
- Improve vascular access management. AVF percentage above catheter benchmark.
- Resolve any state survey or CMS findings.
- Modernize the operating system. Dialysis-specific EMR.
- Run a competitive process. DaVita Inc. (NYSE: DVA), Fresenius Medical Care (NYSE: FMS), US Renal Care, Innovative Renal Care, Satellite Healthcare, Strive Health, plus PE sponsors directly (Bain Capital + Goldman Sachs + Leonard Green, Nautic Partners, Town Hall Ventures + CapitalG).
Free, No Email Required
Get a personalized valuation in 90 seconds
Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.
Open the Valuation Tool →The five pillars of how CT Acquisitions works
Buyer pays our fee. Founders never write a check.
No engagement letter. No upfront cost. No exclusivity contract.
Search funders, family offices, lower-middle-market PE, strategics.
Confidential introductions to the right buyers. No bidding war.
Not 9-12 months. Not 18 months. Months, not years.
No Pitch · No Pressure
Ready to start a confidential conversation?
Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next 60-120 days could look like. No engagement letter. No retainer. Walk at any time.
Start a Confidential Conversation →Frequently asked questions
What is the typical multiple for a dialysis business in 2026?
Single-center low-census dialysis (60-100 patients) typically sells at 5x-7x EBITDA. Multi-center independent groups (2-5 centers, $1.5-4M EBITDA) go 6x-8x. Regional independent platforms (5-15 centers, $4-12M EBITDA) go 7x-9x. Premium scale platforms ($12M+ EBITDA, multi-state, integrated home dialysis, value-based kidney care positioning) reach 8x-11x+.
Who are the active buyers of dialysis businesses right now?
The Big Two own ~80% of US dialysis centers: DaVita Inc. (NYSE: DVA, ~3,000 centers, ~$12B+ revenue) and Fresenius Medical Care (NYSE: FMS, ~2,600 US centers, ~$20B+ global revenue). Third-tier: US Renal Care (PE-backed by Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners, ~$2B+ revenue), Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit). Value-based: Strive Health (Town Hall Ventures + CapitalG/Google), Dialyze Direct (home dialysis). PE sponsors: Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners, Nautic Partners, Town Hall Ventures + CapitalG.
Why is dialysis M&A so concentrated?
DaVita and Fresenius spent two decades consolidating the US dialysis market. ESRD patients are predominantly Medicare-covered, which creates predictable revenue but caps margin. The economics favor scale (water treatment, supply purchasing, nephrologist contracting), and the Big Two have ~80% market share. The remaining ~20% is independent and PE-backed operators competing in regional markets.
What hurts a dialysis business’s valuation most?
Low patient census per center (below 60), hemodialysis-only without home modalities (CMS pushes home dialysis through ETC and KCC value-based models), weak CMS Star ratings (1-2 stars), water-treatment compliance failures, no value-based kidney care positioning, single-state operations without expansion path, single-payer concentration, and open state health department or CMS survey findings.
What are CMS ETC and KCC value-based kidney care models?
ETC (End-Stage Renal Disease Treatment Choices) is a CMS mandatory model in selected Hospital Referral Regions (HRRs) that incentivizes home dialysis (HHD + PD) and transplant. KCC (Kidney Care Choices) is a voluntary CMS value-based model with multiple tracks (KCF Kidney Care First, CKCC Comprehensive Kidney Care Contracting) where participating providers take on financial risk for total cost of care for ESRD and late-stage CKD patients. Premium dialysis platforms increasingly position around these value-based models.
Do I have to pay a broker fee?
No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.
How long does it take to sell a dialysis business?
Once you go to market with a buyer-paid advisor, a typical process runs 6-9 months from initial outreach to closing, with regulatory diligence extending the timeline. Add 12-18 months of preparation work before going to market.
When should I start preparing if I plan to sell in 2027 or 2028?
12-18 months before going to market is the right window. Highest-leverage pre-sale work: build home dialysis (HHD + PD) capability, participate in CMS ETC/KCC value-based models, improve CMS Star ratings and ESRD QIP performance, confirm water-treatment compliance, and document census growth.
Related research
- How to sell an infusion therapy business
- How to sell a specialty pharmacy
- How to sell a home health agency
- How to sell a hospice business
- How to sell a clinical laboratory
- How to sell an imaging center
- Healthcare business valuation
- Which industries is PE buying most in 2026
- Private equity value creation
- Business broker alternative
About the Author
Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch